Table 2.

Maximum Toxicity Grade^a of Related Adverse Events by Treatment Group^b

	Group 1 N=16			Group 2 N=16			Group 3 N=12			Total N=44
	Maximum Toxicity Grade			Maximum Toxicity Grade			Maximum Toxicity Grade			Subjects with Related Adverse Events (%)
	1	2	3	1	2	3	1	2	3
General Disorders and Administration Site Conditions
Injection Site Pain	7	2	1	10	4	0	4	8	0	36 (82)
Malaise	4	1	0	5	1	0	5	2	0	18 (41)
Feeling Hot and Cold	1	1	0	3	0	0	0	0	0	5 (11)
Injection Site Induration	0	0	0	3	0	0	2	0	0	5 (11)
Fatigue	1	2	0	0	0	0	0	0	0	3 (7)
Injection Site Erythema	0	0	0	1	0	0	2	0	0	3 (7)
Injection Site Pruritis	1	0	0	1	0	0	1	0	0	3 (7)
Pyrexia	0	0	0	3	0	0	0	0	0	3 (7)
Feeling Hot	1	1	0	0	0	0	0	0	0	2 (5)
Injection Site Swelling	0	0	0	0	0	0	2	0	0	2 (5)
Rigors	0	0	0	1	0	0	1	0	0	2 (5)
Musculoskeletal and Connective Tissue
Myalgia	3	3	0	8	3	0	6	1	0	24 (55)
Nervous system
Headache	5	1	0	7	0	0	5	0	0	18 (41)
Gastrointestinal
Nausea	0	0	0	3	0	0	0	0	0	3 (7)
Skin and Subcutaneous Tissue Disorders
Erythema	0	0	0	2	0	0	0	0	0	2 (5)
Pruritis	0	1	0	1	0	0	0	0	0	2 (5)
Rash	1	0	0	0	0	0	1	0	0	2 (5)
Investigations
Haemoglobin Decreased	1	0	0	1	0	0	0	0	0	2 (5)

^aNo Toxicity Grade 4 related adverse events were reported

^bSubjects may have had more than one occurrence of the same event, however only one occurrence was counted per subject.